Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab covalently linked to the topoisomerase I inhibitor deruxtecan. From Wikipedia
Breast Cancer Now warns that NICE’s cost-effectiveness framework is blocking life-extending therapies, with the charity calling for urgent policy overhaul.
